Windlas Biotech Reports Q1 FY26 Financial Results: 20% YoY Revenue Growth, 31% PAT Growth

Windlas Biotech Limited, a leading player in the domestic pharmaceutical formulations CDMO industry in India, reported its unaudited financials for the quarter ended June 30, 2025. The company reported a revenue of Rs. 210.1 crores, a YoY growth of 19.9%. EBITDA stood at Rs. 26.5 crores, a growth of 27.0% YoY. PAT stood at Rs. 17.7 crores, a growth of 31.1% YoY. The CDMO vertical contributed approximately 76% to the consolidated revenue, growing by 18% YoY. The Trade Generics & Institutional vertical contributed approximately 21% to the consolidated revenue, growing by 25% YoY. The Exports vertical contributed approximately 3% to the consolidated revenue, growing by 45% YoY. The company is optimistic about the broader Indian pharmaceutical sector and is focused on driving long-term value for shareholders.